Case Report

Crohn’s Disease Following Rituximab Treatment for Follicular Lymphoma in a Patient with Synchronous Gastric Signet Ring Cells Carcinoma: A Case Report and Literature Review

Elisabetta Cavalcanti, PhD¹#, Raffaele Armentano, MD¹, Ivan Lolli, MD²

¹Histopathology Unit of National Institute of Gastroenterology “S. de Bellis,” Research Hospital, Castellana Grotte, Bari, Italy
²Oncology Unit of National Institute of Gastroenterology “S. de Bellis,” Research Hospital, Castellana Grotte, Bari, Italy

Running title: Rituximab induces Crohn’s disease

# Correspondence: Elisabetta Cavalcanti, PhD
Histopathology Unit of National Institute of Gastroenterology “S. de Bellis,” Research Hospital, Via Turi 27, 70013 Castellana Grotte (Ba), Italy
Tel: 39-0804994111
E-mail: elisabetta.cavalcanti@irccsdebellis.it

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an ‘Accepted Article’, doi:10.4143/crt.2020.406
Abstract

Recently, there have been a few reports of rituximab (RTX)-induced Crohn’s disease (CD), but there is no literature available on successful long-term treatment and the clinical outcome of this condition. We retrospectively analyzed the clinical data of a rare case of CD induced by RTX administered as induction and prolonged maintenance therapy of a Follicular Lymphoma (FL), diagnosed synchronously with a gastric signet ring cells carcinoma (SRC), treated at our Hospital.

Keywords

Rituximab, Crohn’s disease, Lymphoma, Gastric signet ring cells carcinoma

Introduction

Crohn’s disease (CD) is an inflammatory bowel disease (IBD) inducing abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Signs and symptoms of CD range from mild to severe, with periods of disease remission. The most common areas affected by CD are the last part of the small intestine and the colon but any segment of the gastrointestinal tract may be affected. The pathogenesis is complex, stemming from genetic susceptibility and mucosal immunity dysfunction as a result of B-cell depletion with a regulatory function to control inflammation [1].

Rituximab (RTX) is an IgG1, anti CD20 chimeric monoclonal antibody (mAb) that induces a selective transient depletion of peripheral CD20-positive B-cells [2]. RTX is part of the standard treatment of patients with B-cell non-Hodgkin’s lymphoma (NHL), including
follicular lymphoma (FL). The mechanisms of action are not fully clarified. A number of antitumor effects have been suggested, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), the induction of apoptosis and sensitization of B-cells to chemotherapy (CT) [3]. Rituximab is usually well tolerated but that adverse events can occur, such as severe mucocutaneous reactions, infusional reactions, progressive multifocal leukoencephalopathy, acute respiratory distress syndrome and cardiovascular events. Recently, Rituximab has also been associated with adverse gastrointestinal effects, including diarrhea and bowel perforation, and recent reports have associated rituximab with the development of de novo inflammatory bowel disease (IBD) [4,5].

Gastrointestinal toxicities are uncommon, indeed, only two reports of rituximab (RTX)-induced Crohn’s disease (CD) have been published in the literature [6,7]. Follicular Lymphoma (FL) is an indolent B-cell lymphoproliferative disorder of transformed follicular center B-cells. It is the second most common subtype of non-Hodgkin lymphoma (NHL) diagnosed in Western countries. The neoplastic cells consist of a mixture of centrocytes (small to medium-sized cells) and centroblasts (large cells). The clinical aggressiveness of the tumor increases with increasing numbers of centroblasts [8]. Gastric signet ring cells carcinoma (SRCC) is defined as an adenocarcinoma in which the majority of cells (>50%) consists of isolated or small groups of malignant non-cohesive cells containing intracytoplasmic mucin. Surgical resection with lymphadenectomy is the treatment of choice for gastric SRC. To date, there has been no evaluation of the sensitivity of gastric SRCC toward chemotherapeutic drugs [9]. Synchronous FL and gastric SRC adenocarcinoma are extremely rare. Here, we present a case of prolonged RTX maintenance treatment-induced Crohn's disease in a patient with synchronous FL and gastric SRC adenocarcinoma.
Case presentation

A 48-year-old male was admitted to our Hospital in July 2009 due to upper abdominal pain, nausea, vomiting and weight loss lasting 4 weeks. The patient had no personal or family medical history of a malignant neoplasm. Gastroscopy revealed an antropyloric neoformation, 3 centimeters in diameter, and biopsy of the gastric lesion was positive for gastric signet ring cell (SRC) carcinoma. Computed tomography (CT) scan confirmed the gastric tumor and showed a coexistent massive mesenteric abdominal mass, with enlarged para-aortic, aorto-caval and coeliac axis lymph nodes. A subtotal gastrectomy with D2 lympho-adenectomy and an excisional mesenteric node biopsy were performed. Histologic examination was consistent with two synchronous malignancies: a poorly differentiated intramucosal gastric SRC adenocarcinoma with embolic micrometastases in 2+/19 nodes of the stomach greater curvature (pT1, N1, M0, stage IB), and a Follicular non-Hodgkin Lymphoma (FL), grade 3a (>15 centroblasts/HPF and centrocytes present in the sample). Immunohistochemical staining of B FL cells revealed the co-expression of CD20, BCL6, BCL2 and CD79a within the B neoplastic follicles and a Ki-67 index >20%. Bone marrow biopsy showed sporadic interstitial aggregates of small lymphoid CD20 and CD3 positive elements. After surgery, the patient showed a good recovery and was discharged on post-operative day 9. The surgical procedure was considered appropriate for early stage I-B GC so no adjuvant chemotherapy was administered. However, a systemic chemotherapeutic regimen was selected for the FL bulky disease. The patient received 7 cycles of a chemotherapy regimen including, on day 1: cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², and vincristine 1.4 mg/m², and on days 1-5: prednisone 100 mg (CHOP regimen). The treatment was well tolerated and induced a complete response. Two years later, a PET scan showed disease recurrence, with mesenteric lymph nodes enlargement and increased 18F-fluorodeoxyglucose (FDG) uptake (max. SUV=7) (Fig. 1). The patient was
treated with eight cycles of R-CNOP (day 1: rituximab 375 mg/m²; day 2: cyclophosphamide 750 mg/m², mitoxantrone 10 mg/m², vincristine 2 mg; days 2-6: prednisone 100 mg). He achieved complete remission and in February 2013 he began maintenance therapy with rituximab (MR), at a dose of 375 mg/m² every 3 months. After eight MR cycles the patient suffered a 2-months period of watery diarrhea with a frequency of 3-4 times a day, of mushy stool that occasionally contained mucus, together with periumbilical and right abdominal pain. A surveillance PET scan, performed at that time, showed an increased activity in the terminal ilium (TI) and mesenteric lymphadenopathy. An ileo-colonoscopy revealed no significant abnormality in the colon mucosa, but macroscopic inflammatory changes in the TI including an erythematous mucosa and aphthous erosions covered with fibrin. Biopsy demonstrated active nonspecific ileitis. Treatment with 5-aminosalicylates (5-ASA) induced a prompt relief of symptoms. He was treated with another 6 cycles of rituximab for a presumed recurrence of the lymphoma. A follow-up TC-enterography, performed 6 months later, showed resolution of the mesenteric adenopathy but the presence of a modest hyper-enhanced bowel wall thickening in the terminal ileum. In September 2017, two months after the last cycle of rituximab, the patient’s clinical conditions worsened. He developed bloody diarrhea, cramping abdominal pain, anemia and weight loss. Endoscopic evaluation showed a transmural involvement of the terminal ilium by an inflammatory process, with mucosal damage, deep ulceration and edema. Histological examination revealed goblet cell depletion and active chronic inflammation with crypt abscess formation (Fig. 2A); the lamina propria was occupied by granulation tissue with dilated, inflamed capillaries. Immunohistochemistry analysis showed a total depletion of the CD20 positive B cells in the ileal mucosa (Fig. 2B), an increased cellularity of CD3⁺ T lymphocytes in the tonaca propria and intraepithelial mucosa (Fig. 2C) and moderate excess of enlarged macrophages (CD68⁺), exclusively in the lamina propria ( Fig. 2D), suggesting
exacerbation of the CD. Pathological features were in keeping with active Crohn's disease.

Rituximab therapy was interrupted. He was treated with budesonide and 5-ASA, and responded well. After 10 weeks the patient was asymptomatic and an endoscopic control showed slight signs of inflammation of the terminal ilium. A follow-up PET scan was negative for activity in the TI. He has remained in remission for 30 months without any adverse events. At present he is taking 5-ASA as maintenance therapy and the clinical conditions have clearly improved.

Discussion

Synchronous gastric SRC and abdominal FL is rare and there is no standard treatment strategy for patient management. A number of factors such as age, performance status, pathological features and tumor staging must be taken into consideration during decision making, in terms of which cancer to treat first and what is the optimal therapy. In our case the patient underwent a combination of treatments, including surgical excision and chemotherapy. Subtotal gastrectomy with D2 lymphadenectomy was considered appropriate for the early stage I-B gastric SRC treatment, while a systemic chemotherapeutic regimen was selected based on the FL bulky disease. FL is the second most common form of non-Hodgkin lymphoma (NHL) [10]. Management is characterized by a risk-adapted therapy based on the stage of the disease and the patient's symptoms. For patients with a high tumor burden, the standard treatment option is immuno-chemotherapy. The addition of the anti-CD20 monoclonal antibody (mAb) RTX to chemotherapy has yielded a higher rate of complete remission and improved survival. In addition, RTX as maintenance therapy after the induction regimen improves progression-free survival (PFS) in high-tumor burden patients [11]. The use of B-cell depletion therapy with
RTX has shown some success in the treatment of autoimmune diseases such as rheumatoid arthritis, by reducing the adaptive immune response against self. The elimination of B-cells to treat autoimmunity also has a disadvantageous side, as it results in the depletion of regulatory B-cells (B-regs) that suppress inflammation [12]. Some adverse events have been reported after RTX therapy, such as cutaneous reactions, cardiomyopathies, interstitial pneumonia, infections and progressive multifocal leukoencephalopathy. Recently, J.D. Eckmann et al described patients with rituximab-associated de novo colitis [13], raising the hypothesis that B-cells may play a protective role of the intestinal mucosa. There are only a few reports in the literature of the induction or exacerbation of IBD by RTX. In a patient with refractory ulcerative colitis (UC), Goetz et al [14] reported that RTX exacerbated the disease by locking IL-10 producing B-cells, suggesting an important anti- rather than pro-inflammatory role of B-cells in UC. To our knowledge, only three cases of RTX induced CD have been previously reported in the literature (Table 1): two cases in elderly patients treated with three-months MR over a 2-years period and one case of a 15-year old boy with refractory nephrotic syndrome receiving 4 doses of RTX over a 2-years period. Compared with the cases reported previously, our patient was treated with a three-monthly MR for a longer period, fourteen doses in four and half years. At the time, the increased uptake at the mesenteric lymph nodes and at TI level, detected by the PET-scan performed after eight MR cycles, suggested lymphoma recurrence and the incorrect assessment induced to continue treatment with RTX whereas, most likely, the finding was correlated with a CD in initial phase, a rare and unexpected complication. In particular this case demonstrates the importance of being alert to the possibility of CD in presence of abdominal pain, weight loss and diarrhea during RTX treatment. In the present report, the histopathological and immunohistochemical analysis suggests that exacerbation of CD may be related to the total depletion of CD20 positive B-cells in the intestinal mucosa and high tonaca.
propria and intraepithelial infiltration of the T-cells (CD3+) and macrophages (CD68+). B and T cells have been involved in the pathogenesis of IBD. It has been suggested that B-cells may not have a proinflammatory role in IBD; indeed, they may have a protective effect, reducing inflammation by producing the antiinflammatory cytokine IL-10. Most studies performed in IBD experimental models suggest that B-regs suppress mucosal inflammation, either by secreting cytokines such as interleukin (IL)-10 or by interacting with T-cells. Inhibition of B–T cell interaction caused by B-cell depletion may lead to T-regulatory cell dysfunction, and the subsequent activation of Th1 and Th17 cells. As a consequence, Crohn’s disease could develop due to a dysregulated mucosal immune response [15]. This immune dysregulation of the gastrointestinal tract may potentially lead to Crohn’s disease as a secondary complication in susceptible RTX patients. Nevertheless, the fact remains that RTX is an effective treatment for B-cell lymphoma.

In this case, we propose that Crohn's disease was caused by an abnormal dysfunction of mucosal immunity that resulted in a disturbed intestinal balance secondary to the use of RTX. Therefore, inflammatory bowel disease should be considered if severe abdominal symptoms with weight loss are observed following RTX administration.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Acknowledgements

This study has been supported by Ricerca corrente 2019.
Ethical statement

Written informed consent was obtained from the patient prior to publication of this case report and all procedures performed were in accordance with the ethical standards of the institutional research committee (IRCCS Giovanni Paolo II, Bari, Italy)
References


10) Dada R. Diagnosis and management of follicular lymphoma: A comprehensive review.


Fig. 1. PET scan showing massive 18F-fluorodeoxyglucose (FDG) uptake (max. SUV = 7) and mesenteric lymph nodes enlargement (black arrow).
Fig. 2. (A) Active-chronic inflammation with ulceration, crypt abscess formation and goblet cell depletion (5× magnification, hematoxylin and eosin staining), (B) After rituximab therapy, CD20 cells staining was negative, (C) Immunohistochemistry with an anti-CD3 antibody demonstrated numerous intraepithelial mucosal T-cells after therapy, (D) High tonaca propria and intraepithelial infiltration of macrophages (CD68⁺) (10× magnification).
<table>
<thead>
<tr>
<th>First Author</th>
<th>Year</th>
<th>Cases</th>
<th>Age</th>
<th>Gender</th>
<th>Type of Colitis</th>
<th>Indication for Rituximab</th>
<th>Presenting gastrointestinal symptoms</th>
<th>Treatment with Rituximab (month)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poornima Varma</td>
<td>2017</td>
<td>2</td>
<td>80</td>
<td>F</td>
<td>Crohn Disease</td>
<td>Lymphoma</td>
<td>Diarrhea, Abdominal pain, Weight loss, fever</td>
<td>three monthly maintenance rituximab over 2-years period</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>74</td>
<td>M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Keishi Morita</td>
<td>2019</td>
<td>1</td>
<td>15</td>
<td>M</td>
<td>Crohn Disease</td>
<td>refractory nephrotic syndrome</td>
<td>Abdominal pain, localized in the area of the umbilicus, watery stools, watery diarrhea, abdominal pain, anemia, weight loss and dilated cardiomyopathy</td>
<td>Over a 2-year period, the patient received four doses of RTX</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>three monthly RTX</td>
</tr>
<tr>
<td>Present case</td>
<td>2020</td>
<td>1</td>
<td>59</td>
<td>M</td>
<td>Crohn Disease</td>
<td>follicular B cell non-Hodgkin lymphoma</td>
<td>three monthly maintenance rituximab over 4 and half years period</td>
<td></td>
</tr>
</tbody>
</table>